| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 24, 2025CE MDR approval for basivertebral nerve ablation therapy designed to provide long-lasting relief from single procedure
HEMEL HEMPSTEAD, United Kingdom, 24 July, 2025 — Boston Scientific Corporation (NYSE: BSX) today announced CE mark and first procedure in Europe with the Intracept Intraosseous Nerve Ablation...
-
Jul 10, 2025Positive guidance for the Boston Scientific FARAPULSE™ Pulsed Field Ablation System marks expansion of minimally invasive treatment options for growing number of atrial fibrillation patients in the UK.
HEMEL HEMPSTEAD, United Kingdom, 10 July 2025 – Boston Scientific Corporation (NYSE: BSX) today welcomed guidance1 supporting the use of pulsed field ablation (PFA) for the treatment of atrial...
-
Mar 3, 2025
Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ --...
-
Feb 17, 2025FARAWAVE™ NAV Ablation Catheter and FARAVIEW™ Software combine with Boston Scientific mapping system to provide mapping during pulsed field ablation
LONDON, United Kingdom, 17 February, 2025 – Boston Scientific Corporation (NYSE: BSX) today announced it has received CE mark for the navigation-enabled FARAWAVE™ NAV Ablation Catheter for the...
-
Jan 16, 2025
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed...